Focused On-demand Library for Regulator of telomere elongation helicase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Novel helicase-like

Alternative UPACC:

Q9NZ71; A2A397; A2A398; B4DRM5; B4DYM3; B4E3N6; E1P5J4; E1P5J5; Q5JTV3; Q5JTV4; Q9BW37; Q9H402; Q9H4X6; Q9NX25; Q9NZ73; Q9UPR4; Q9Y4R6


Regulator of telomere elongation helicase 1 (RTEL1), also known as Novel helicase-like, plays a crucial role in telomere-length regulation, DNA repair, and maintaining genomic stability. It acts as an anti-recombinase, limiting crossover during meiosis and ensuring telomere dynamics and stability by counteracting telomeric G4-DNA structures.

Therapeutic significance:

RTEL1's involvement in diseases like Dyskeratosis congenita and Pulmonary fibrosis, linked to defective telomere maintenance, highlights its potential as a target for therapeutic strategies. Understanding RTEL1's function could lead to breakthroughs in treating these genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.